Reported 2 days ago
TransMedics Group Inc. (NASDAQ:TMDX) has emerged as a leading growth stock, gaining 129% in share price this year and reporting an 83% revenue increase in 2024. The company is focused on revolutionizing organ transplantation through its National OCS Program, positioning itself for substantial growth with projections of achieving $1.2 billion in revenue by 2028. Analysts maintain a positive outlook on TMDX, encouraging its innovative approaches to expand the donor pool and increase transplant volumes, with ambitious goals set for future kidney care platforms.
Source: YAHOO